97Ru-transferrin uptake in tumor and abscess
- 46 Downloads
The uptake of97Ru-transferrin (Ru-TF) in tumor and abscess bearing animals was compared with67Ga-citrate (Ga),123I-transferrin (I-TF), and several other plasma proteins. Maximal concentration in tumor of Ru-TF in mice was three times higher than67Ga-citrate (16.80±4.20 vs 5.08±0.58% D/g) although it occurred later (24 h compared with67Ga which reached its maximum 2 h after injection). Whole body autoradiography (WBARG) with103Ru-transferrin (103Ru-TF) in tumor and abscess bearing rats demonstrated details of the distribution within these lesions. Turpentine-induced abscesses in the rabbits could be visualized with the gamma camera as early as 30 min post-injection of Ru-TF. It seems, therefore, that Ru-TF can be used for tumor and abscess localization. The results indicate that Ru-TF may have some advantages over67Ga-citrate because of the higher concentration in the lesions.123I-transferrin reached a concentration in tumor similar to67Ga (6.89±1.67 vs 5.08±0.58% D/g) but had a very low tumor to blood ratio (0.64). The three compounds investigated (Ru-TF, I-TF and ionic Ga, which binds instantaneously to TF in vivo) have a common lignad, transferrin. It appears, therefore, that tumor affinity is a property of the radionuclide-ligand complex rather than of the radionuclide itself.
KeywordsPublic Health Radionuclide Nuclear Medicine Maximal Concentration Plasma Protein
Unable to display preview. Download preview PDF.
- 1.Chen DCP, Newman B, Turkall RM, Tsan MF (1982) Transferrin receptors and gallium-67 uptake in vitro. Eur J Nucl Med 7:536–540Google Scholar
- 2.Oster ZH, Som P, Gil MC (1981) Ru-97-DTPA: A new radiopharmaceutical for cisterography. J Nucl Med 22:269–273Google Scholar
- 3.Oster ZH, Som P, Gil MC (1981) Ru-97-DMSA for delayed renal imaging. Radiology 141:185–190Google Scholar
- 4.Schachner ER, Gil MC, Atkins HL (1981) Ru-97-Hepatobiliary agents for delayed studies of the biliary tract. 1: Ru-97-PIPIDA- J Nucl Med 22:352–357Google Scholar
- 5.Som P, Oster ZH, Fairchild RG (1981) Biodistribution of Ru-97 labeled DTPA, DMSA and transferrin. In: Third International Radiopharmacentical Dosimetry Symposium. HHS Publication FDA 81-8166, pp 346–363Google Scholar
- 6.Som P, Oster ZH, Matsui K (1981) Comparative uptake of clotting factors in experimental animals. J Nucl Med 22:55Google Scholar
- 7.Som P, Oster ZH, Yonekura Y, Meyer MA, Fand J, Brill AB (1982) Applications of whole body autoradiographic technique in radiopharmaceutical research. In: Proceedings 3rd World Congress Nucl Med Biol. Vol IV, Raynaud C (ed) Pergamon Press, Paris, pp 3257–3261Google Scholar
- 8.Srivastava SC, Richards P, Meinken GE, Larson SM, Grunbaum Z (1981) Tumor uptake of radioruthenium compounds. In: Radiopharmaceuticals: Structure activity relationship. Spencer R (ed), Grune and Stratton, New York, pp 207–223Google Scholar
- 9.Srivastava SC, Richards P, Meinken GE, Atkins HL, Sewatkar A, Ku TH (1980) Ruthenium-97 labeled compounds-A new class of radiopharmaceuticals. In: Frontiers in Nuclear Medicine. Horst W, Wagner HN, Jr, Buchanan JW (eds). Berlin Heidelberg New York: Springer, pp 123–133Google Scholar